Document Detail


Medical therapy in heart failure--is polypharmacy necessary?
MedLine Citation:
PMID:  15329755     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The concept of heart failure has undergone several paradigm shifts in the past few decades. Therapeutic targets directed at the heart pump have shifted to circulatory haemodynamics to the current neurohormonal model. Consequently, therapeutic modalities have similarly evolved alongside clinical trials. Successive trials have tested newer drugs in addition to established therapies, resulting in evidence-based treatments necessitating polypharmacy. Optimal heart failure therapy has therefore become increasingly complex. It is only after understanding the precise modes of drug action, as well as the relevance of the design of clinical trials, will physicians hopefully be able to tailor the medical therapy optimally towards the individual patient with heart failure.
Authors:
B W K Kwok
Related Documents :
22008495 - Predictive value of microvolt t-wave alternans for cardiac death or ventricular tachyar...
15734765 - Diuretic usage in heart failure: a continuing conundrum in 2005.
16036035 - Quality of care and outcomes in acute decompensated heart failure: the adhere registry.
18360065 - Clinical impact of adherence to guidelines on the outcome of chronic heart failure in j...
8475305 - Retrograde catheterization of the ureter without cystoscopic assistance: preliminary ex...
57785 - Association of ventricular extrasystoles and ventricular tachycardia with idioventricul...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of the Academy of Medicine, Singapore     Volume:  33     ISSN:  0304-4602     ISO Abbreviation:  Ann. Acad. Med. Singap.     Publication Date:  2004 Jul 
Date Detail:
Created Date:  2004-08-26     Completed Date:  2004-11-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7503289     Medline TA:  Ann Acad Med Singapore     Country:  Singapore    
Other Details:
Languages:  eng     Pagination:  444-50     Citation Subset:  IM    
Affiliation:
Department of Cardiology, National Heart Centre, 17 Third Hospital Avenue, Singapore 168752.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Aldosterone Antagonists / therapeutic use
Algorithms
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Cardiotonic Agents / therapeutic use
Heart Failure / drug therapy*,  physiopathology
Hemodynamics
Humans
Hydrazones / therapeutic use
Polypharmacy*
Pyridazines / therapeutic use
Ventricular Function, Left
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Aldosterone Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coronary artery disease: comprehensive evaluation by cardiovascular magnetic resonance imaging.
Next Document:  Stem cell cardiomyoplasty: state-of-the-art.